Showing results (1-10 of 27) with videos related to
Sort By:
Pageof 3
Clinical Lymphoma|April 10, 2004
Allogeneic hematopoietic stem cell transplantation for lymphomaRobert M Dean, Michael R BishopCurrent Hematology Reports|August 7, 2003
Graft-versus-host disease: emerging concepts in prevention and therapyRobert M Dean, Michael R BishopBiology of Blood and Marrow Transplantation : Journal of the American Society for Blood and Marrow Transplantation|January 27, 2009
Assessment of the hematopoietic cell transplantation comorbidity index in non-Hodgkin lymphoma patients receiving reduced-intensity allogeneic hematopoietic stem cell transplantationSeth M Pollack, Seth M Steinberg, Jeanne Odom, et al.British Journal of Haematology|May 3, 2016
Is rituximab sub-optimally dosed in indolent B cell lymphoma?Yazeed Sawalha, Basel Rouphail, Xuefei Jia, et al.Leukemia & Lymphoma|September 15, 2021
The impact of socioeconomic disparities on the use of upfront autologous stem cell transplantation for mantle cell lymphomaYazeed Sawalha, Tomas Radivoyevitch, Xuefei Jia, et al.Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|November 13, 2008
Association of serum interleukin-7 levels with the development of acute graft-versus-host diseaseRobert M Dean, Terry Fry, Crystal Mackall, et al.British Journal of Haematology|February 29, 2020
Characterisation and prognostic impact of immunoparesis in relapsed multiple myelomaRajshekhar Chakraborty, Lisa Rybicki, Megan O Nakashima, et al.Leukemia & Lymphoma|July 12, 2017
A phase I trial of bortezomib in combination with everolimus for treatment of relapsed/refractory non-Hodgkin lymphomaBrian T Hill, Mitchell R Smith, Meredeth Shelley, et al.Cancer|December 31, 2009
Correlation of pretransplant and early post-transplant response assessment with outcomes after reduced-intensity allogeneic hematopoietic stem cell transplantation for non-Hodgkin's lymphomaMichael R Bishop, Robert M Dean, Seth M Steinberg, et al.Clinical Lymphoma, Myeloma & Leukemia|August 10, 2017
Grade 3 Follicular Lymphoma: Outcomes in the Rituximab EraMoaath Mustafa Ali, Lisa Rybicki, Laila Nomani, et al.Pageof 3